Nanoform significantly improved cash flow, keeping it on track with its financial objectives
Public source
Publisher name
Public post
๐๐ข๐ญ๐ก ๐ฌ๐ข๐ฑ ๐ฆ๐จ๐ง๐ญ๐ก๐ฌ ๐๐๐ก๐ข๐ง๐ ๐ฎ๐ฌ ๐๐ง๐ ๐๐ฑ๐๐ข๐ญ๐ข๐ง๐ ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐๐ก๐๐๐, ๐ฐ๐'๐ซ๐ ๐ญ๐๐ค๐ข๐ง๐ ๐ ๐ฆ๐จ๐ฆ๐๐ง๐ญ ๐ญ๐จ ๐ซ๐๐๐ฅ๐๐๐ญโฆ
Company
Nanoform
Global experts in nanotechnology and drug particle engineering
- Industry
- Pharmaceutical Manufacturing
- Location
- Helsinki, FI
- Company size
- 51โ200 employees
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoformโs platform technologies. The company focuses on reducing clinical attrition and on enhancing drug moleculesโ performance through its nanoforming technologies and formulation services. Nanoformโs capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications.
See moreLatest activity
Latest activity from Nanoform
8 signals
Presence & Recognition
Nanoform is exhibiting at CPHI Milan 2026 to explore nanoparticle-engineering technologies supporting high-concentration biologics, IV to SC administration, reduced injection volumes, patient convenience and adherence, bioavailability for challenging molecules, and new formulation and lifecycle management opportunities for complex small molecules.
Products & Services
Nanoform initiated discussions with CDMO partners regarding sterile GMP manufacturing capabilities for its biologics platform
Products & Services
Nanoform entered into the first exclusivity deal for its ultra-high concentration biologics formulation technology
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited generated $5.4 million in operating cash flow in FY26 while increasing working capital to support higher customer demand and larger domestic and international supply commitments.
Capital & Finance
Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S has reached the market for new products and invested in facilities and capacity
Capital & Finance
SomnoMed Limited
SomnoMed Limited reduced manufacturing production times by over 50% over the past two years.
Capital & Finance
Organon
Organon achieved $280M in revenue exposure through a single governing forum built with a small team and an $800K budget.
Capital & Finance
Immunophotonics, Inc.